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Abstract
Overdose due to opioid abuse is an ever increasing problem, especially in the United States, with the last few
years seeing a dramatic rise in the number of synthetic opioid-related deaths. The pure opioid antagonist
naloxone has been used in a clinical setting as an antidote to opioid overdose for decades. Recent data suggest
that the number of patients requiring multiple doses of naloxone is growing likely caused by the increased
number of intoxications with potent synthetic opioids such as fentanyl and its derivatives. Treating clinicians
in both emergency departments and pre-hospital settings should be aware that they may need to escalate to
higher doses of naloxone, with repeat doses or IV infusions required, when treating patients who have
overdosed on synthetic opioids. Moving forward, a combination of improved access to naloxone in a pre-
hospital setting, an increase in community-based training, including the likely requirement of rapid or higher
dose naloxone administration for treatment of synthetic opioid overdose, and a better understanding of the
toxicology of high potency synthetic opioids, are required to decrease the number of fatalities stemming from
the current opioid crisis.
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ABSTRACT
Overdose due to opioid abuse is an ever increasing problem, especially in the United States, with
the last few years seeing a dramatic rise in the number of synthetic opioid-related deaths. The pure
opioid antagonist naloxone has been used in a clinical setting as an antidote to opioid overdose for
decades. Recent data suggest that the number of patients requiring multiple doses of naloxone is
growing likely caused by the increased number of intoxications with potent synthetic opioids such
as fentanyl and its derivatives. Treating clinicians in both emergency departments and pre-hospital
settings should be aware that they may need to escalate to higher doses of naloxone, with repeat
doses or IV infusions required, when treating patients who have overdosed on synthetic opioids.
Moving forward, a combination of improved access to naloxone in a pre-hospital setting, an
increase in community-based training, including the likely requirement of rapid or higher dose
naloxone administration for treatment of synthetic opioid overdose, and a better understanding of
the toxicology of high potency synthetic opioids, are required to decrease the number of fatalities




The United States, sadly, is in the midst of an opioid epi-
demic. Data released by the National Center of Health
Statistics in December 2017 show that deaths from opi-
oid overdose exceeded 42,000 in 2016, an increase of
more than 27% on 2015 [1] with increases seen for all
classes of opioids (Figure 1). Of greatest concern, how-
ever, is the rapid increase in the number of deaths from
synthetic opioids, such as fentanyl and its derivatives.
An agonist at all opioid receptors fentanyl is fifty to a
hundred times more potent than morphine [2,3] with
respiratory depressant effects that peak in 5–15 min and
a dose-dependent duration of action [4]. Synthetic opi-
oid deaths doubled from 9580 in 2015 to 19,413 in 2016
and contributed to the accelerated rise in opioid deaths
since 2013 (Figure 1) [1]. The trend appears unabated in
2017. In Ohio during January–February 2017 90% of the
281 unintentional overdose fatalities tested positive to
the presence of fentanyl with the majority of decedents
testing positive to more than one type of fentanyl deriva-
tive [5].
The US Government recently acknowledged the opi-
oid crisis at both a state and federal level, with six states
taking the additional step of declaring the issue a state of
emergency [6]. Both Alaska and Maryland specifically
acknowledged the role synthetic opioids are playing, and
five of the six states used their emergency declaration to
promote an increase in access to the opioid antidote
naloxone [6]. The approaches taken to promote this
improved access to naloxone vary greatly by state and
local area. Some of the programs introduced include: the
training and education of emergency medical services,
law enforcement personnel and lay-persons; supply of
naloxone to emergency medical services and law
enforcement agencies; lay-person access to naloxone via
pharmacy without a prescription; and programs to
directly supply naloxone to addicts upon institutional
release [6,7].
Clinicians have used the opioid antagonist naloxone
as an antidote to opioid overdose for decades. As a com-
petitive antagonist at the m-opioid receptor it effectively
reverses clinical signs of opioid intoxication. However,
naloxone can precipitate withdrawal effects in opioid-
addicted individuals. The US Food and Drug Adminis-
tration (FDA) approved its use as an intravenous, intra-
muscular, or subcutaneous injection of naloxone
hydrochloride in 1971, and more recently in the form of
the Evzio auto-injector in 2014, designed for intramus-
cular or subcutaneous administration, and Narcan
Nasal Spray, designed for intranasal administration, in
2015.
The recent approval and increased availability of
intranasal naloxone products has altered the pre-hospital
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care setting in the past few years. Lay-persons are able to
regularly administer these products as they eliminate the
risk of needle-stick injury. However, the prices of both
Narcan Nasal Spray (»$US135 for a two pack) [8] and
the Evzio auto-injector (»$US3800 for a two pack) [8]
are hindersome to their use. Claims from the Narcan
Nasal Spray manufacturer that the drug is affordable as
“80% of current prescriptions have a co-pay of $20 or
less” [9] are unlikely to accurately represent the current
pricing situation as opioid addicts who are not able to
purchase naloxone due to its inhibitive cost are not
reflected in these statistics. Continuing to ease access to
naloxone, including a decrease in price, allowing non-
prescription supply and providing training for both lay-
persons and advanced life support providers is a critical
step in the attempt to decrease the number of deaths
stemming from the opioid epidemic.
US National Emergency Medical Service data show
that the number of patients requiring multiple naloxone
doses is trending upwards [10] likely as a result of
increasing intoxication with synthetic opioids. Literature
evidence of cases involving higher than usual doses of
naloxone is summarized in Tables 1 (case studies) and 2
(retrospective case series). Gussow 2016 suggested that
protocols starting with very low doses or naloxone
(<0.4 mg) may need to be rethought, providing anec-
dotal evidence that patients with presumed carfentanil
exposure required up to 18 mg of naloxone to reverse
the effects of opioid intoxication [11]. The general con-
versational nature of this report with no analytical analy-
sis or data provided shows the importance of ensuring
unusual cases are fully reported in the literature with
naloxone doses and full toxicological blood and urine
screening results in order to better inform changes to
naloxone dosage protocols.
The FDA currently recommends an initial dose of
0.4–2 mg of naloxone via IV or IM, with some emer-












All opioids Heroin Natural and semisynthec Methadone Synthec opioids excluding methadone
Figure 1. Drug overdose deaths in the United States, 1999–2016, by opioid category. Deaths involving more than one drug may be
counted in more than one category. Data taken from the NCHS Data Brief, December 2017 [1].
Table 1. Case studies involving higher than usual doses of naloxone in patients with synthetic opioid intoxication.




U-47700 insufflated and IV 2 mg IN – no response; 2 mg IV - response
(4 mg total)
Discharged next day; LC-MS drug
confirmation
[13] 36-year-old male, altered
mental status, pinpoint




2 mg IV – awoke but eventually mental status
declined; 2 mg IV – again roused but
mental status declined; 2 mg IV followed by
1.5mg/hour infusion (>7.5 mg total)
Admitted to ICU; Identity of drug







shown to contain fentanyl
2 mg IN + 1 mg IV – no significant response
(3 mg total)
Eighteen further patients over eight days,
one death, 3/18 received 5 mg
naloxone total bolus dose, 4/18
received a naloxone infusion
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lower end of this dosing regimen [17,18]. However, in
cases of an unknown intoxication with opioids resulting
in poor or incomplete response to naloxone, or known
intoxication with synthetic opioids, clinical staff may
need to escalate to higher doses more quickly than they
would have previously with opioids such as heroin. In
addition, multiple doses or intravenous infusions are
often required as fentanyl and its derivatives have a lon-
ger biologically active half-life than naloxone [4].
In the face of the rising opioid epidemic, the obvious
difficulty facing clinical staff is that often they do not
know identity of the opioid causing the intoxication. A
number of illicit opioids, including fentanyl, do not pro-
duce a positive result on a standard drug urine screen
and staff have to rely solely on the opioid toxidrome to
identify cases of suspected opioid intoxication. Adding
to this complexity is the fact that the 200 known syn-
thetic derivatives of fentanyl, some of which are up to
10,000 times more potent than morphine, are increas-
ingly sold as heroin or in combination with heroin with-
out the knowledge of the user [19,20]. We suggest
beginning with smaller doses of naloxone (0.4 mg IV),
followed by a rapid escalation to higher doses (2 mg) if
no response is observed within 2–3 min.
Pre-hospital settings would likely require similar pro-
tocols with lay-persons or emergency medical personnel
administering naloxone via the intramuscular or intra-
nasal route. It is therefore important to ensure an
explicit explanation of the likely higher doses of nalox-
one required for treatment of synthetic opioid in educa-
tion and training programs. Additionally, treating staff
need access to adequate volumes of naloxone to deal
with this eventuality.
Moving forward we require improved access to nalox-
one in the pre-hospital setting, increased community-
based training including the likely requirement of rapid/
higher dose naloxone administration for treatment of
synthetic opioid overdose, and a better understanding of
the toxicology of high potency synthetic opioids, to
reduce the number of fatalities stemming from the cur-
rent opioid crisis.
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